Skip to main content

Patient-centered support and assistance

We believe patient well-being requires care and guidance at every step along the treatment journey.



From our research and development process to our personalized patient support programs, AbbVie ensures our science and our medicines serve the people who need them most. This means continuing to analyze our clinical trials to ensure they reflect a diversity in race, ethnicity, age, and gender. It also means assisting with financial hurdles to get our medicines to patients and supporting patients along with their families, caregivers and communities, all of whom play a pivotal role during a patient’s health journey. Our robust programs support the health of those we serve and the sustainability of our business.

Diversity in clinical trials

Every year, tens of thousands of patients worldwide participate in clinical trials of potential AbbVie medicines. It is these participants that we are able to bring new medicines to more patients.

Our clinical trials should reflect the populations we serve. Ensuring diversity means we can better meet the needs of our patients both today and tomorrow. We are focused on improving clinical research diversity, bringing research and treatment options to groups of patients who have been historically underserved.

We rely on real-world data and evidence to help ensure participation in AbbVie-sponsored clinical trials appropriately represents the age, gender, race and ethnicity of patients living with the diseases we are studying. This includes:

  • Evaluating our clinical trial protocol eligibility criteria against real-world datasets to ensure we are designing inclusive study protocols and enabling under-represented populations to volunteer for our clinical trials.
  • Addressing any identified diversity gaps through a tailored plan that may include enhanced community partnerships, clinical research staff education, investigator trainings, new site selection strategies and targeted patient outreach.
  • Routinely re-assessing clinical study demographics to determine if our efforts to ensure participation of under-represented populations have made an impact, pivoting to different strategies if necessary.
  • Continuing to refine our clinical trial diversity and inclusion strategies based on analytics and ensuring every team has access to regional indication demographics, including AbbVie resources to help resolve previously identified diversity gaps.

Health outcomes & research

We work closely with payers, providers, regulators and health technology assessment organizations to build shared understanding of how our medicines create value and impact overall health budgets. Once clinical trials are complete and a new medicine is approved, AbbVie’s Health Economics and Outcomes Research team uses real-world data and economic modeling techniques to examine how the medicine works under actual conditions and how it compares to already-available medicines.

The HEOR team seeks to understand the patient perspective on living with their condition and integrates the patient voice through clinical outcome assessments, our medical product development programs and real-world research. In addition, the HEOR team develops customized health economic models to understand the budget impact of new medicines and whether new treatments are cost-effective compared to other existing therapies.

Real-world data helps us evaluate a medicine’s safety and effectiveness, guiding recommendations such as label enhancements and extensions. Economic data informs our sense of its value, and patient experience data focuses on signs, symptoms, functioning and quality of life measures. Our health economists seek to understand the impact of illness from a patient and healthcare system perspective, current treatment patterns and unmet needs, patient behaviors and product performance in settings and populations that are representative of routine clinical practice. 

 

Using real-world health outcomes to understand the full value of treatments.

Using research and data to quantify the patient experience and factor these outcomes into medical decision making.

Patient access & assistance

We believe that people who need our medicines should be able to get them. We evaluate our pricing decisions on an annual basis, considering a range of factors on a product and country-specific basis, and offer a range of programs that help ensure access to our medicines. Our corporate growth strategy is primarily driven by reaching more patients with innovative new medicines.

We provide co-pay assistance (regardless of income) to all patients with commercial insurance, with the majority of patients paying $5-10 per month. More than 90% of commercial patients are utilizing the co-pay assistance program. We also make donations to independent charitable foundations that provide co-pay assistance to patients in need, regardless of what type of therapy they are on.

Through our U.S. patient assistance program, myAbbVie Assist, we provide free AbbVie medicine to qualifying patients in the U.S. who lack insurance or whose health plans limit coverage for our treatments. For our immunology treatments, the income eligibility requirements are 600% of the Federal Poverty Level (FPL) or less than $159,000 for a household of four people. For all our other medicines, eligibility requires 500% FPL or less than $132,000 for a household of four people. These programs help 99% of uninsured patients who seek our assistance and provided free medicine. In 2020, myAbbVie Assist supported nearly 155,000 patients. We also partner to build local healthcare capacity, increase the quality and frequency of health worker training, and educate patients about disease awareness, symptom management and treatment options.

 

Making a difference in patients’ lives, Erica Shipley is on a mission to care through myAbbVie Assist

Patient education & support

We know the power of education in disease management, so we create, fund, and support programs that equip patients and their families with the resources they need to understand their diseases. The goal is to reduce medication errors and improve treatment adherence. With research as our foundation, we use behavioral science to enhance the ways we teach patients to use our medicines. Online programs and educational materials also help increase understanding of the healthcare environment and facilitate connections with patient organizations and other patients.

We have systems in place to respond to patient questions rapidly and provide patients with robust resources that are easy to navigate, so they feel empowered, informed, and can focus on their health.
 

  • Through a wide range of disease and country-specific programs, we equip patients, their families and caregivers with the knowledge and resources to understand their disease and the treatment they have been prescribed. Some programs also provide lifestyle management support to further promote health. All patient support programs are tailored to the needs and regulations in each country and patient community.
  • Some programs may help patient and physicians verify insurance coverage for select AbbVie medicines that require prior authorization. These programs can help pateitns access financial assistance, and in specific situations, may dispense medicines directly to patients.
  • AbbVie partners with health care teams on interventions to help build health care capacity, increase the quality and frequency of health worker training, make connections with patient organizations and educate patients about disease awareness, symptom management, treatment options and support activities.

Uncovering the true adverse effects on individuals and society when patients discontinue their medicine.

Striving for patient centricity, down to the packaging.

+57M

Patients treated with AbbVie medicine
each year

~155,000

Number of patients received their AbbVie medicines from our programs at no cost

275

AbbVie patient support programs globally

 

Data from year-end 2020

For the Well-Being of Our Patients